Hopitaux Universitaires Of Geneva

Genève, Switzerland

Hopitaux Universitaires Of Geneva

Genève, Switzerland

Time filter

Source Type

Patent
University of Geneva and Hopitaux Universitaires Of Geneva | Date: 2017-01-27

The present invention relates to new BARD1 isoforms specific to lung cancer and colorectal cancer, a method for detecting thereof and a method for treating and/or preventing lung cancer and colorectal cancer.


Patent
Hopitaux Universitaires Of Geneva and University of Geneva | Date: 2012-03-09

The present invention relates to isolated polypeptides comprising: (i) a protein transduction domain consisting of ZEBRA or a fragment thereof that retains the capacity of internalization, (ii) at least one CD4^(+) epitope; and (iii) at least one CD8^(+) epitope. It also relates to antigen presenting cells loaded with said polypeptides, and the use thereof in immunotherapy including prevention and/or treatment of cancers or infectious diseases.


Patent
University of Geneva and Hopitaux Universitaires Of Geneva | Date: 2015-10-15

The present invention relates to isolated polypeptides comprising: (i) a protein transduction domain consisting of ZEBRA or a fragment thereof that retains the capacity of internalization, (ii) at least one CD4^(+) epitope; and (iii) at least one CD8^(+) epitope. It also relates to antigen presenting cells loaded with said polypeptides, and the use thereof in immunotherapy including prevention and/or treatment of cancers or infectious diseases.


Patent
Hopitaux Universitaires Of Geneva and University of Geneva | Date: 2011-08-17

The present invention relates to new BARD1 isoforms specific to lung cancer and colorectal cancer, a method for detecting thereof and a method for treating and/or preventing lung cancer and colorectal cancer.


Patent
University of Geneva and Hopitaux Universitaires Of Geneva | Date: 2012-04-23

An apparatus for the treatment and/or prevention of corneal diseases includes an applicator head. The applicator head includes a radiation source capable of exciting a non-toxic chromophore. A control is operable to activate the radiation source to radiate, wherein at least one of the following two conditions is met: the applicator head includes a sensor capable of measuring a signal dependent on a position of the applicator head relative to the cornea; or, the applicator head is configured to be in physical contact with the cornea. The control is operable to activate the radiation source to radiate depending on a signal measured by the sensor or to activate the radiation source when the applicator head touches the cornea, respectively.


Van Beers B.E.,Hopitaux Universitaires Paris Nord Val Of Seine | Pastor C.M.,Hopitaux Universitaires Of Geneva | Hussain H.K.,University of Michigan
Journal of Hepatology | Year: 2012

Gadolinium ethoxybenzyl dimeglumine (Gd-EOB-DTPA, Primovist® in Europe and Eovist® in the USA) is a liver-specific magnetic resonance imaging contrast agent that has up to 50% hepatobiliary excretion in the normal liver. After intravenous injection, Gd-EOB-DTPA distributes into the vascular and extravascular spaces during the arterial, portal venous and late dynamic phases, and progressively into the hepatocytes and bile ducts during the hepatobiliary phase. The hepatocyte uptake of Gd-EOB-DTPA mainly occurs via the organic anion transporter polypeptides OATP1B1 and B3 located at the sinusoidal membrane and biliary excretion via the multidrug resistance-associated proteins MRP2 at the canalicular membrane. Because of these characteristics, Gd-EOB-DTPA behaves similarly to non-specific gadolinium chelates during the dynamic phases, and adds substantial information during the hepatobiliary phase, improving the detection and characterization of focal liver lesions and diffuse liver disease. This information is particularly relevant for the detection of metastases, and for the detection and characterization of nodular lesions in liver cirrhosis, including early hepatocellular carcinomas. Finally, GD-EOB-DTPA-enhanced magnetic resonance imaging may provide quantitative assessment regarding liver perfusion and hepatocyte function in diffuse liver diseases. The full potential of GD-EOB-DTPA-enhanced magnetic resonance imaging has to be established further. It is already clear that GD-EOB-DTPA-enhanced magnetic resonance imaging provides anatomic and functional information in the setting of focal and diffuse liver disease that is unattainable with magnetic resonance imaging enhanced with non-specific contrast agents. © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.


Duthon V.B.,Hopitaux Universitaires Of Geneva
Orthopaedics and Traumatology: Surgery and Research | Year: 2015

Inaugural traumatic patellar dislocation is most often due to trauma sustained during physical or sports activity. Two-thirds of acute patellar dislocations occur in young active patients (less than 20years old). Non-contact knee sprain in flexion and valgus is the leading mechanism in patellar dislocation, accounting for as many as 93% of all cases. The strong displacement of the patella tears the medial stabilizing structures, and notably the medial patellofemoral ligament (MPFL), which is almost always injured in acute patellar dislocation, most frequently at its femoral attachment. Lateral patellar glide can be assessed with the knee in extension or 20° flexion. Displacement by more than 50% of the patellar width is considered abnormal and may induce apprehension. Plain X-ray and CT are mandatory to diagnose bony risk factors for patellar dislocation, such as trochlear dysplasia or increased tibial tubercle-trochlear groove distance (TT-TG), and plan correction. MRI gives information on cartilage and capsulo-ligamentous status for treatment planning: free bodies or osteochondral fracture have to be treated surgically. If patellar dislocation occurs in an anatomically normal knee and osteochondral fracture is ruled out on MRI, non-operative treatment is usually recommended. © 2014 Elsevier Masson SAS.


Van Delden C.,Hopitaux Universitaires Of Geneva
Current Opinion in Organ Transplantation | Year: 2014

PURPOSE OF REVIEW: The purpose of this study is to provide an overview of bacterial biliary tract infections in liver transplant recipients with a focus on pathogenesis and conservative treatment strategies. RECENT FINDINGS: The development of interventional endoscopic and radiologic interventions has improved the outcome of conservative treatments for bile tract strictures and bilomas. However, recent data show an important rise of infections with multidrug-resistant (MDR) pathogens in liver transplant recipients. SUMMARY: Both recurrent cholangitis and infected bilomas are bacterial biliary tract infections in liver transplant recipients responsible for significant morbidity and graft loss, which require a multidisciplinary approach. Risk factors for biliary tract strictures and bilomas formation have recently been identified. With the improved outcome of a conservative management including prolonged and/or recurrent antibiotic treatments, the risk of selecting resistant pathogens is increased. There is an urgent need to develop new strategies to reduce the risk of secondary infections by MDR isolates in liver transplant recipients. © 2014 Wolters Kluwer Health.


Shah D.,Hopitaux Universitaires Of Geneva
Expert Review of Medical Devices | Year: 2011

The advent of catheter ablation has revolutionized the treatment of supraventricular cardiac arrhythmias, including in the last few years, atrial fibrillation. The discovery of electrically active sleeves of atrial myocardium extending into the pulmonary veins has led to the development of pulmonary vein ostial ablation, with the aim of electrically isolating or 'walling-off the arrhythmogenic tissue. Despite different innovations, the most commonly used technique is the composite multiple-point ablation lesion created with a fundamentally simple radiofrequency energy-delivering ablation catheter. The high recurrence rate and low efficacy of current ablation procedures may be traced in large part to the inherent variability in individual lesion size with this technology. Arguably, real-time lesion monitoring, optimization and prediction are necessary to achieve significant improvements in efficacy and safety for catheter ablation of atrial fibrillation.


Patent
Hopitaux Universitaires Of Geneva | Date: 2014-05-13

Dynamic external fixator comprising a pair of rods (1) made of a radiolucent material, each rod (1) comprising a base (10), preferably with an opening (13), a stem (11) extending from the base (10), with a sliding groove (14) extending along a longitudinal axis of the stem (11); and stopping means (12, 2) between the base (10) and the stem (11); a pair of springs (3), each spring (3) being arranged on the stem (11) of one of the rods (1) and abutting against the stopping means (12, 2); proximal attachment means (K1) for attaching the base (10) of each rod (1) to a first position; distal attachment means (K2) for attaching the stem (11) of each rod (1) to a second position, wherein the distal attachment means (K2) are inserted into the spirals of the spring (3) and through the sliding groove (14) of each of the rods (1), such that turning the spring (3) around the stem (11) allows adjusting a distraction force between the proximal attachment means (K1) and the distal attachment means (K2); and method for attaching such a dynamic external fixator.

Loading Hopitaux Universitaires Of Geneva collaborators
Loading Hopitaux Universitaires Of Geneva collaborators